Developing Biomarkers in Pancreatic Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pancreatic Cancer
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Enrollment
- 53
- Locations
- 3
- Primary Endpoint
- Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapy
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
RATIONALE: Studying samples of tissue in the laboratory from patients with cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is studying biomarkers in patients with pancreatic cancer.
Detailed Description
OBJECTIVES: * To determine whether the cellular localization of BRCA1 can predict how patients with pancreatic cancer will respond to cytotoxic agents (e.g., fluorouracil or gemcitabine hydrochloride) or radiotherapy. * To identify pre-treatment markers that can be used to correlate with clinical outcomes of survival and recurrence. * To determine if a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue can now be applied to the pancreatic cancer population. OUTLINE: Tissue samples from biopsies performed during pancreatectomy are collected from the Vanderbilt Ingram Cancer Center Human Tissue Acquisition Core for laboratory biomarker studies. Proteins secreted by cancer cells and/or cancer-associated cells are studied by extracting and identifying secreted cytokines and growth factors from biopsy tissue. The integrity of the DNA repair pathway in pancreatic cancer is analyzed by Rad51 and phosphorylated DNA-PK foci formation. Markers are correlated with clinical outcome. Patients are followed for recurrence, relapse, and death from disease.
Investigators
A Bapsi Chakravarthy, MD
Associate Professor; Radiation Oncologist
Vanderbilt-Ingram Cancer Center
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapy
Time Frame: following collection of all pancreatic tissue specimens and patient outcome data
Examine the location of BRCA1 in the cells and determine if this location predicts patient response to the chemotherapy drugs given
Secondary Outcomes
- Correlation of pre-treatment markers with survival and recurrence(at expiration date of final patient enrolled)
- Application of a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue to the pancreatic cancer population(upon collection of pancreatic tissue for each patient)